This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research Article
Identification of best suitable repurposed drugs considering mutational spectra at RdRp (nsp12), 3CLpro (nsp 5) and PLpro (nsp 3) of SARS-CoV-2 in Indian population
Pritha Bhattacharjee
Environmental Epigenomics Lab, Department of Environmental Science, University of Calcutta, 35 Ballygunge Circular Road, Kolkata – 700019
Corresponding Author
ORCiD: https://orcid.org/0000-0002-4623-7746
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background and Objective: COVID-19 originated in Wuhan, China and expanded to different geographical location of the world with variation in its sequence due to mutation, consequent alteration in different protein structures; resulting in different interaction with the host body. The highly infectious and diverge character of the virus makes it imperative to identify the promising inhibitory compounds for RdRp, 3CLpro and PLpro as suitable antiviral drug target so that viral duplication can be prevented in the host body.
Methods: RdRp, 3CLpro and PLpro sequences of Indian patients were retrieved from the database and MSA was employed to identify mutation at nsp 3, nsp 5 and nsp 12. Protein structures were modeled considering all possible combination of sequences abundant in India and docking was performed with repurposed drugs, currently under trial for COVID-19, using Autodock Vina to find out the suitable ones considering the mutational spectra of SARS-CoV-2 in India.
Results: PLpro is found to be most vulnerable to mutations with four mutations found in >5% studied population whereas in 3CLpro none observed at the frequency > 5%, so far. Two mutations were reported among Indian population (>5%) at RdRp. Therefore 3CLpro and RdRp were further analysed as a suitable target for repurposed drugs. Elbasvir has come up as the most suitable drug to inhibit the activity of RdRp in Indian population, followed by Remdesivir and Methylprednisolone. TMC 310911, Lopinavir and Elbasvir again, found to be the best candidates for inhibiting 3CLpro.
Interpretation and Conclusions: Remdesivir and Lopinavir(alone or in combination with Ritonavir), the most popular drugs of choice at recent times may be suitable to be used in Indian population, considering the mutational variations in Indian population. Among others, Elbasvir, TMC 310911 and Methylprednisolone are good choices for treating COVID-19.
Keywords
COVID-19, Molecular Docking, Mutational Spectra, Protease, RNA dependent RNA polymerase, SARS-CoV-2 in India.
Figure 1
Figure 2
Figure 3
Figure 4
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 08 Jun, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint. It has not completed peer review.
Research Article
Identification of best suitable repurposed drugs considering mutational spectra at RdRp (nsp12), 3CLpro (nsp 5) and PLpro (nsp 3) of SARS-CoV-2 in Indian population
Pritha Bhattacharjee
Environmental Epigenomics Lab, Department of Environmental Science, University of Calcutta, 35 Ballygunge Circular Road, Kolkata – 700019
Corresponding Author
ORCiD: https://orcid.org/0000-0002-4623-7746
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 08 Jun, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background and Objective: COVID-19 originated in Wuhan, China and expanded to different geographical location of the world with variation in its sequence due to mutation, consequent alteration in different protein structures; resulting in different interaction with the host body. The highly infectious and diverge character of the virus makes it imperative to identify the promising inhibitory compounds for RdRp, 3CLpro and PLpro as suitable antiviral drug target so that viral duplication can be prevented in the host body.
Methods: RdRp, 3CLpro and PLpro sequences of Indian patients were retrieved from the database and MSA was employed to identify mutation at nsp 3, nsp 5 and nsp 12. Protein structures were modeled considering all possible combination of sequences abundant in India and docking was performed with repurposed drugs, currently under trial for COVID-19, using Autodock Vina to find out the suitable ones considering the mutational spectra of SARS-CoV-2 in India.
Results: PLpro is found to be most vulnerable to mutations with four mutations found in >5% studied population whereas in 3CLpro none observed at the frequency > 5%, so far. Two mutations were reported among Indian population (>5%) at RdRp. Therefore 3CLpro and RdRp were further analysed as a suitable target for repurposed drugs. Elbasvir has come up as the most suitable drug to inhibit the activity of RdRp in Indian population, followed by Remdesivir and Methylprednisolone. TMC 310911, Lopinavir and Elbasvir again, found to be the best candidates for inhibiting 3CLpro.
Interpretation and Conclusions: Remdesivir and Lopinavir(alone or in combination with Ritonavir), the most popular drugs of choice at recent times may be suitable to be used in Indian population, considering the mutational variations in Indian population. Among others, Elbasvir, TMC 310911 and Methylprednisolone are good choices for treating COVID-19.
Figure 1
Figure 2
Figure 3
Figure 4